GENE ONLINE|News &
Opinion
Blog

2017-12-29|

December 29, 1957: American Immunologist Bruce Beutler Was Born

by GeneOnline
Share To

Bruce Beutler (December 29, 1957 – present) is an American immunologist and geneticist who first discovered cytokine TNFαand applied genetic engineering technique to develop recombinant antibodies which has been widely used in treating various autoimmune diseases. Together with Jules A. Hoffmann, Beutler received one-half of the 2011 Nobel Prize in Physiology or Medicine for their discoveries concerning the activation of innate immunity. Beutler is currently Director of the Center for the Genetics of Host Defense at the University of Texas Southwestern Medical Center in Dallas, Texas, and is professor in the Department of Immunology and chairman of the Department of Genetics at Scripps Research at La Jolla, California.

Reference
https://en.wikipedia.org/wiki/Bruce_Beutler

Image Source
https://en.wikipedia.org/wiki/Bruce_Beutler

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
R&D
Vaccine Development Has No Limits, the Application Direction of mRNA After the Nobel Prize
2023-10-17
Svante Pääbo Wins Physiology or Medicine Nobel Prize for Human Evolution Discoveries
2022-10-06
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top